323PSubcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis. (23rd October 2018) - Kümmel, S; Tondini, C A; Abraham, J; Nowecki, Z I; Itrych, B; Hitre, E; Karaszewska, B; Juarez, A; Morales-Vásquez, F; Pérez García, J M; Cardona-Huerta, S; Heinzmann, D; et al.